Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia  by Green, Jacob et al.
Kidney International, Vol. 60 (2001), pp. 1182–1196
Evidence for a PTH-independent humoral mechanism in
post-transplant hypophosphatemia and phosphaturia
JACOB GREEN, HILLA DEBBY, ELEANOR LEDERER, MOSHE LEVI, HUBERT K. ZAJICEK,
and TOVA BICK
Department of Nephrology, Rambam Medical Center, B. Rappaport Faculty of Medicine, Technion, Israel Institute of
Technology, Haifa, Israel; Division of Nephrology, Department of Medicine, University of Louisville, Louisville, Kentucky,
Department of Medicine, University of Texas, Southwestern Medical Center, and Nephrology Section, Veterans Affairs Medical
Center, Dallas, Texas, USA
groups 2, 4, and 5 vs. groups 1 and 3). Time-course analysisEvidence for a PTH-independent humoral mechanism in post-
revealed that the up-regulation of Na/Pi protein by sera fromtransplant hypophosphatemia and phosphaturia.
groups 2, 4, and 5 was observed as early as four hours ofBackground. Patients undergoing successful kidney trans-
incubation, whereas augmented abundance of Na/Pi mRNAplantation often manifest overt hypophosphatemia associated
was only seen after eight hours of incubation. The addition ofwith exaggerated phosphaturia during the early post-transplant
PTH (1-34) to sera from groups 2, 4, and 5 abolished theperiod (2 weeks to 3 months). The mechanism for this phenom-
enon has not been fully elucidated. We tested the hypothesis augmented expression of NaPi protein. We labeled OK cell
that a circulating serum factor [non-parathyroid hormone (non- surface membrane proteins with N-hydroxysuccinimide bound
PTH)], which operates during chronic renal failure (CRF) to to biotin (NHS-SS-biotin). Biotinylated transporters incubated
maintain phosphate (Pi) homeostasis, can increase fractional with the different sera were precipitated by strepavidin and
excretion of Pi (FEPO4) in normal functioning kidney grafts identified by Western blot analysis. Cells incubated in sera
during the early post-transplant period, thereby causing phos- from group 2 showed increased membrane bound transporter
phaturia and hypophosphatemia. when compared with control sera, whereas the intracellular pool
Methods. Five groups of patients were studied: control sub- of the transporter was comparable between the two groups.
jects (group 1, N  16), “early” (2 weeks to 1 month) post- Conclusion. A non-PTH circulating serum factor (possibly
transplant patients (group 2, N  22), “late” (9 to 12 months) phosphatonin) that increases FEPO4 during CRF is also respon-
post-transplant patients (group 3, N  14), patients with ad- sible for phosphaturia and hypophosphatemia in the early pe-
vanced CRF (glomerular filtration rate  30 to 40 mL/min; riod following successful kidney transplantation. The putative
group 4, N  8), and patients who suffered from end-stage factor inactivates Na/Pi activity along with inhibition of the
renal failure and were treated by chronic hemodialysis (group 5, transporter trafficking from the cell membrane into the cytosol.
N  14). Group 2 manifested significant hypophosphatemia
and phosphaturia when compared with groups 1 and 3 (Pi 
0.9  0.003 mg/dL, FEPO4  68 5%, P  0.0005 vs. groups 1
and 3). Sera were taken from each of the five subject groups Patients receiving renal transplant from either living
and applied to the proximal tubular opossum kidney (OK) related or cadaveric donors frequently (50 to 80% inci-
cells. The activity of Na/Pi-type 4 (that is, OK-specific type II dence) develop hypophosphatemia [1–3]. These patients
transporter) was evaluated by measuring Na-dependent 32Pi
often exhibit phosphaturia [2], decreased renal phos-flux. The expression of Na/Pi type II mRNA and the abundance
phate (Pi) threshold (TmPO4/GFR), and increased ratesof Na/Pi protein were determined by Northern and Western
blot assays, respectively. of fractional excretion of Pi (FEPO4) in the face of stable
Results. When compared with sera from groups 1 and 3, and normal glomerular filtration rates (GFRs). Thus far,
10% sera taken from groups 2, 4, and 5 (incubated overnight the mechanism for post-transplant hypophosphatemiawith OK cells) inhibited 32Pi flux by 25 to 30% (P  0.0003).
has not been fully elucidated. It has been thought, how-Both Na/Pi mRNA and the expression of Na/Pi protein were
ever, that this syndrome is somehow linked to disorderedmarkedly augmented under the same conditions (P  0.05
regulation of renal tubular reabsorption of Pi. Pi reab-
sorption in the renal proximal tubule, which is a major
Key words: renal transplantation, Na/Pi cotransport, opossum kidney
mechanism in the maintenance of overall Pi homeostasis,cells, parathyroid hormone, phosphatonin, fractional excretion of phos-
phate, proximal tubule. is a Na-dependent, secondary active process involving
Na-Pi cotransport across the brush-border membraneReceived for publication October 16, 2000
(BBM) as a rate-limiting step. The recently cloned type IIand in revised form January 29, 2001
Accepted for publication April 6, 2001 Na/Pi cotransporter has been shown to govern the rate
of proximal tubular Pi reabsorption in several species. 2001 by the International Society of Nephrology
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Table 1. Study groupsAlterations in the activity of this cotransporter account
for physiological and pathophysiological changes in prox- Study group N
imal tubular Pi reabsorption [4–7]. (1) Normal controls 16
(2) “Early” post-transplant patients (2 weeks–1 month) 22Parathyroid hormone (PTH) leads to a reduction in
(3) “Late” post-transplant patients (9–12 months) 14the expression of type II Na/Pi cotransport at the BBMs,
(4) Patients with advanced CRF (GFR 40 mL/min) 8
which accounts for the phosphaturic action of PTH [7]. (5) Patients treated by chronic hemodialysis 14
Given this property of PTH, it has been postulated that Abbreviations are: CRF, chronic renal failure; GFR, glomerular filtration rate.
increased PTH activity during chronic renal failure
(CRF) may be the major mechanism responsible for
maintaining Pi balance during CRF [8, 9]. According to
this hypothesis, post-transplant hypophosphatemia was well as the sequential regulation of Na/Pi protein and
attributed to persistent hyperparathyroidism (HPT), that mRNA under these circumstances were measured.
is, incomplete involution of hyperplastic glands produced
by renal failure prior to transplantation would cause
METHODShypophosphatemia and increased phosphaturia during
Subjectsthe early post-transplant period [10]. Several studies,
however, have documented that protracted HPT cannot Five groups of human subjects were recruited for our
account for the phenomenon of post-transplant hypo- study (Table 1). Clinical and relevant laboratory data
phosphatemia since it can be seen in transplant patients for each of the groups are listed in Table 2. The groups
with normal PTH levels. Moreover, transplant recipients were matched for gender and age.
failed to decrease Pi excretion in the urine even when Patients who had undergone kidney transplantation
PTH was suppressed by calcium infusion [2]. In addition, were recruited into the study at both the “early” post-
the phosphaturia following kidney transplantation could transplant period (that is, 2 weeks to 1 month following
not be ascribed to the effects of nephrectomy or to the transplantation) and during the “late” post-transplant
influence of immunosuppressive drugs [2]. period (that is, 9 to 12 months following transplantation).
With this background in mind, we sought to determine The early group received 14 cadaveric transplants and
whether an alternative non-PTH humoral mechanism 8 living related transplants, whereas the late groups re-
could account for the entity of post-transplant hypophos- ceived 8 cadaveric and 6 living related transplants. The
phatemia. Most recently, the concept of “phosphatonin” two groups of transplant patients were matched with re-
has been introduced to describe a circulating factor that spect to the duration of previous dialysis (time on dialy-
does not belong to the group of the “classic” regulators of sis for the early group was 5.1  0.3 years, and for the
Pi balance (for example PTH, vitamin D, calcitonin) and late group was 4.75  0.2 years). The etiology of renal
that exerts an inhibitory effect on the activity of type II failure in the early group was chronic glomerulonephri-
Na/Pi [11, 12]. The putative “phosphatonin” has been
tis (5 patients), polycystic kidneys (4 patients), diabetic
implicated in the pathogenesis of phosphaturia and hy-
nephropathy (3 patients), obstructive uropathy (2 patients),pophosphatemia in various diseases such as tumor-
vasculitis (1 patient), analgesic nephropathy (1 patient),induced osteomalacia and X-linked hypophosphatemic
and unknown etiology (6 patients). The late post-trans-rickets [11]. Based on this knowledge, we hypothesize
plant patients had suffered from chronic glomerulo-that another factor, in addition to PTH (phosphatonin?),
nephritis (4 patients), polycystic kidneys (3 patients),is responsible for maintaining Pi homeostasis in CRF.
interstitial disease of undetermined origin (2 patients),During the early post-transplant period (up to several
amyloidosis caused by familial Mediterranean fevermonths following transplantation), persistence of this
(1 patient), and the etiology of renal failure was not deter-factor in the serum of transplant patients with normal
mined in four patients. All transplant patients manifestedfunctioning kidneys would account for phosphaturia and
normal values of GFR (based on serum creatinine andhypophosphatemia in these patients. To test our hypoth-
measurements of creatinine clearance), and none had ex-esis, sera were obtained from control subjects, transplant
perienced an episode of graft rejection during the studypatients during both early (2 weeks to 1 month) and late
period. All patients were maintained on a triple immuno-(9 to 12 months post-transplant) periods, patients with
suppressive regimen consisting of prednisone, cyclospo-advanced CRF (GFR 40 mL/min), and patients main-
rine A (CsA), and mycophenolate mofetil (MMF). Thetained on chronic hemodialysis. These sera were applied
dose of prednisone was 25 mg/day at two weeks followingto opossum kidney (OK) cells, a cell line with proximal
transplantation and was decreased to 10 to 15 mg attubular characteristics [13]. These cells possess Na/Pi-4,
one month following transplantation and thereafter. CsAthat is, an OK-specific type II Na/Pi cotransporter [14],
microemulsion (Neoral) was given at a dose of 5 mg/kgand have been extensively used for the investigation of
the regulation of Na/Pi [13, 15]. The Na/Pi activity as to achieve a trough level of 180 to 220 ng/mL (measured
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Table 2. Clinical and laboratory details
Group 1 Group 2 Group 3 Group 4 Group 5
control “early” post-transplant “late” post-transplant CRF Dialysis
Age range 45 (25–63) 52 (35–72) 55 (40–69) 48 (32–77) 54 (28–68)
Gender M/F 9/7 14/8 8/6 4/4 8/6
GFR mL/min 1100.02 980.04 1010.05 370.04 —
Serum calcium mg/dL 9.20.04 9.40.03 9.70.02 8.90.05 8.50.03
Serum Pi mg/dL 3.80.04 0.90.003a 2.60.04 5.10.04 6.20.8
FEPO4 % 180.4 685a 240.6 573 —
Serum albumin g/dL 4.10.03 3.90.02 4.20.01 3.80.04 3.70.03
Urine volume mL/24 hr 240018 225011 232015 212014 —
Serum PTH, pg/mL (range)
(normal values 10–65 pg/mL) 150.3 640.4 342.1 40–354 65–860
(45–224) (24–115)
Serum 1,25(OH)2D3, pg/mL
(normal levels 20–50 pg/mL) 340.8 310.9 360.7 271.2 ND
Blood pH 7.390.02 7.420.04 7.40.06 7.380.08 7.410.05
Serum bicarbonate mEq/L 220.4 23.20.6 24.10.32 220.6 230.6
a P  0.0005 vs. corresponding values in groups 1 and 3.
by a monoclonal cyclosporine-specific radioimmuno- tions of  blockers,  blockers, and calcium-channel
blockers. None of the patients received vitamin D prepa-assay). The dose of MMF was 2 g/day.
Table 2 shows the overt hypophosphatemia and phos- rations.
The patients maintained on chronic intermittent hemo-phaturia in the early post-transplant patients as compared
with all other groups. The phosphaturia is expressed as dialysis were treated in our dialysis unit. The average du-
ration on dialysis was 3.5 0.6 years, and all patients wereFEPO4 calculated as (UPi  PCr  100)/(PPi  UCr), where
U is urine, P is plasma, and Cr is creatinine. Patients treated three times a week for four hours at each session.
The cause for end-stage renal failure was chronic glomer-with marked hypophosphatemia (less than 1.5 mg/dL Pi)
were treated by an oral preparation containing a mixture ulonephritis (5 patients), ADPKD (2 patients), chronic
interstitial disease (2 patients), hypertensive nephroscle-of sodium and potassium salts of Pi for at least three
months in an attempt to normalize Pi levels. rosis (1 patient), secondary amyloidosis caused by famil-
ial Mediterranean fever (1 patient), and unknown etiol-Table 2 also shows the range of PTH serum levels
(whole molecule, measured by a two-site radioimmuno- ogy (3 patients). None of the patients had diabetes
mellitus or diabetic nephropathy. Serum levels of PTHassay) in the post-transplant patients. In the early group,
PTH levels were within normal range (60 pg/mL) in ranged between 65 and 860 pg/mL, but 6 out of the 14
patients included in the study had PTH levels less than15 of 22 patients, while in the late group, PTH levels
were normal in 9 of 14 patients. twice the upper limit of normal (that is, 120 pg/mL).
The normal control subjects were recruited from theThe patients with CRF were recruited from the CRF
clinic of the Rambam Medical Center (Technion School staff of the department of nephrology at our institution.
The study protocol was approved by the Institutionalof Medicine, Haifa, Israel). GFR was 30 to 40 mL/min
estimated by the Cockcroft and Gault formula: [140 age Review Board on Human Investigation of the Rambam
Medical Center (Technion School of Medicine), and all(years)]  [weight (kg)]/[72 serum creatinine (mg/dL)].
For females, the derivative was reduced by 15%. Of the subjects participating in this study provided written in-
formed consent before the start of the study. In all sub-CRF patients, three patients had chronic glomerular dis-
ease. One patient had analgesic nephropathy. One pa- jects, venous blood (15 to 20 mL) was drawn between
7:00 and 9:30 a.m. In the dialysis patients, blood wastient suffered from autosomal-dominant polycystic kid-
ney disease (ADPKD), and in three patients, the cause of drawn in the morning, one hour before starting dialysis.
For serum preparation, whole blood samples were cen-CRF could not be determined. None of the patients had
diabetic nephropathy. All patients were maintained on a trifuged at 500  g for 10 minutes, filtered through a
45 	m filter (Sartorious AG, 37070 Goettingen, Ger-special diet that was prescribed to them by our dieti-
tian. The composition of the diet was the following (for many), heat inactivated at 56
C for 30 minutes, aliquoted,
and stored at 20
C until use.60 kg body weight): Ca, 800 mg; P, 600 mg; K, 60 mmol;
Na, 119 mmol; protein, 40 g; and energy, 2000 kcal. The
Cell culturerange of PTH levels in the CRF patients was 40 to
354 pg/mL, but in four patients, PTH levels were normal. Opossum kidney cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented withPatients were maintained on Pi binders and antihyper-
tensive medications, which included varying combina- 10% fetal calf serum (FCS), 2 mmol/L l-glutamine,
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50 IU/mL penicillin, and 50 	g/mL streptomycin at a hu- nized suspension was centrifuged at 50,000  g for 40
minutes at 4
C. The pellet was resuspended in 100 	Lmidified atmosphere of 5% CO2, 95% air at 37
C. The
sterile culture medium (DMEM), FCS, and antibiotic so- of 50 mmol/L mannitol with 10 mmol/L HEPES-Tris
(pH 7.2), and the protein concentration was determinedlutions were purchased from Biological-Industries (Kib-
butz Beith-HaEmek, Israel). Subculture was performed by the Bio-Rad protein assay.
weekly using 0.5% trypsine/0.2% ethylenediaminetetra-
SDS-polyacrylamide gel electrophoresisacetic acid (EDTA; Biological-Industries). Confluent cells
and immunoblottingwere incubated for the desired time periods with DMEM
containing 2 to 10% human serum from each of the experi- Twenty micrograms of membranous protein isolated
from OK cells were denatured for five minutes at 95
Cmental groups as listed in Table 1. For time course analy-
ses, cells were incubated for varying time periods (0.5, 1, in 2  loading buffer solution containing 4% SDS, 20%
vol/vol glycerol, 200 mmol/L dithiothreitol (DTT), and2, 4, 8, or 24 h) with 10% human sera. For determination
of the effect of Pi concentration, cells were incubated for 125 mmol/L Tris-HCl (pH 6.8), separated on 7% poly-
acrylamide [SDS-polyacrylamide gel electrophoresis (SDS-20 hours in DMEM containing either 1 or 0.1 mmol/L Pi.
PAGE)] gels and electrotransferred onto nitrocellulose
Determination of Na/Pi cotransport activity paper (Schleicher & Schuell, Dassel, Germany). After
an overnight blockage with 5% nonfat dry milk in Tris-Sodium-dependent transport of Pi was determined in
cells grown to confluency in 24-multiwell plates. Uptake buffered saline (TBS)/0.1% Tween-20, Western blots
were incubated with polyclonal antisera that were raisedsolution consists of 140 mmol/L NaCl, 5 mmol/L KCl,
1 mmol/L MgCl2, 1.5 mmol/L CaCl2, and 10 mmol/L against the C-terminal 12 amino acids of the published
Na/Pi-4 (opossum) sequence (kindly provided by Dr. E.HEPES (pH 7.4) and 0.1 mmol/L KH232PO4 (1 mCi/mL;
Amersham, Buckinghamshire, UK). For transport assay, Lederer, University of Louisville, KY, USA) at a dilution
of 1:2000 or with a rabbit anti Glut-1 (Chemicon Interna-growth medium was removed by aspiration, and cells were
rinsed three times in uptake solution containing 140 tional Inc., Temecula, CA, USA) at a dilution of 1:2000 or
with mouse anti-actin monoclonal antibody (Chemiconmmol/L tetramethyl-ammoniumchloride (TMA) instead
of NaCl. Uptake was performed at 37
C for five minutes International Inc.) at a dilution of 1: 1.000 for two hours
at room temperature. Then, the nitrocellulose was(representing initial linear rate) by the addition of uptake
solution plus 0.1 mmol/L 32PO4. Sodium-independent Pi washed four times with TBS/0.1% Tween-20 at room
temperature and incubated for one hour with a 1:10,000uptake (that is, 32P uptake in the presence of 140 mmol/L
TMACl replacing NaCl) contributed 2 to 4% of total dilution of an anti-rabbit IgG labeled with horseradish
peroxidase (Sigma, St. Louis, MO, USA). The nitrocellu-uptake and was therefore negligible. The reaction was
stopped by aspiration of the uptake medium and washing lose membrane was then washed four times with TBS/
0.1% Tween-20 at room temperature, and the signals werethe cells three times with ice-cold stop solution containing
140 mmol/L NaCl, 1 mmol/L MgCl2 and 10 mmol/L detected by enhanced chemiluminescence (ECL; Beit-
Haemek, Israel) according to the manufacturer’s proto-HEPES (pH 7.4). Cells were solubilized with 0.1% so-
dium dodecyl sulfate (SDS), and radioactivity was deter- col using Kodak X-OMAT AR film (Eastman Kodak,
Rochester, NY, USA). The Na/Pi protein-specific bandsmined by liquid scintillation. For determination of glucose
transport, cells were incubated for five minutes at 37
C were then quantitated by laser scanning densitometry.
with uptake solution containing 0.2 mmol/L 3H-glucose
Isolation of total RNA and Northern blot analysis(1 mCi/mL; Dupont, New England Nuclear, NEN, Bos-
ton, MA, USA). Each transport reaction was measured Total RNA samples were prepared from OK cells
monolayers grown in 25 cm2 flasks that were incubatedin triplicates.
for 4, 8, or 24 hours with 10% human sera from the
Isolation of OK cell membranes experimental groups listed in Table 1, using Tri-Reagent
as recommended by the supplier (Sigma Chemical Co.)For these experiments, OK cells were seeded in six-well
plates. Confluent cells were incubated for 0.5, 1, 2, 4, or according to the method of Chomczynski and quantified
by absorbance at 260 nm [16]. The integrity of the RNA24 hours in media containing 10% human sera from the
experimental groups listed in Table 1. Subsequently, cells and the accuracy of the spectrophotometric determina-
tions were assessed by visual inspection of the ethidiumwere washed with cold 0.9% NaCl and 10 mmol/L Tris-
HCl (pH 7.4, TBS) and then scraped off the well with bromide-stained 28S and 18S ribosomal RNA bands after
electrophresis through 1% (wt/vol) agarose-2.2 mol/L5 mmol/L HEPES-KOH (pH 7.4) and supplemented with
a protease inhibitor cocktail tablet (Boehringer Mann- formaldehyde gel. Samples containing 20 	g of total
RNA were prepared with 2 loading buffer (2MOPS,heim, Mannheim, Germany). For homogenization, the
cell suspension was passed five times through a 10 mL 3% formaldehyde, 15 	g/mL ethidium bromide, and
30% formamide), heated at 65
C for five minutes, andsyringe connected to a 20-gauge needle. The homoge-
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loaded onto 1% agarose gel (1  MOPS, 3% formal- PBS) strepavidin-agarose beads (Pierce). After beads
precipitation, the remaining supernatant was retained asdehyde). RNA was transferred with 20 standard saline
citrate (SSC) to nylon, positively charged, blotting mem- the intracellular fraction. The pellet was then washed
three times in wash solution A containing 50 mmol/Lbranes (Boehringer-Mannheim) by standard capillary
blotting techniques and immobilized by heating at 80
C NaCl, 5 mmol/L EDTA, 50 mmol/L Tris, and a protease
inhibitor mix, twice in wash solution B containing 500for two hours. The cDNA probes corresponding to the
2 kilobase (kb) EcoRI transcript that encodes the OK mmol/L NaCl, 20 mmol/L Tris, and a protease inhibitor
mixture, and finally once with wash solution C containingcell type II Na/Pi cotransporter and the 0.9 kb BamHI
PSTI cyclophyllin were excised from pSPORTI and pBlue- 10 mmol/L Tris and a protease inhibitor mix. Precipitated
proteins were dissociated from the beads by exposingscript transcripts, respectively, run on an agarose gel and
cleaned using a DNA isolation kit. The excised fragments them to 2  loading buffer at 95
C for five minutes,
yielding the surface fraction. Western blotting was thenwere labelled by random priming using [-32P] deoxy-
CTP (3000 Ci/mmol; Amersham International, Ayles- performed on the total, intracellular, and surface frac-
tions, and bands were visualized using ECL.bury, UK) using a random Primer DNA labeling kit.
Prehybridization was carried out for four hours at 68
C
Statistical analysisin hybridization solution (7% SDS, 10% polyethylene
glycol, 1.5  SSPE and 0.25 mg/mL denatured herring The experiments were performed at least five times
in triplicates. The results express as mean  SEM, andsperm DNA). Labeled probes were added to the hybrid-
ization solution and rotated for 20 hours in a hybridiza- the data were analyzed with the Student t test. A proba-
bility level of P  0.05 was regarded as significant.tion oven. After hybridization, the blots were washed
twice at room temperature with 2  SSC/0.1% SDS,
once at 55
C with 0.5  SSC/0.1% SDS, and once at
RESULTS
60
C with 0.1  SSC/0.1% SDS, and autoradiography
Patients during the early post-transplant period mani-was performed at70
C with Kodak X-OMAT AR film.
fest marked hypophosphatemia and exaggerated phos-The mRNA level for Na/Pi was quantitated by densitom-
phaturia when compared with control subjects and withetry on a phosphoimager and normalized to the corre-
patients in the late post-transplant period (Table 2). Tosponding cyclophylin mRNA.
explore possible mechanisms for this phenomenon, con-
Biotinylation and strepavidin precipitation fluent OK cells were incubated overnight (20 h) with
DMEM containing 10% sera obtained from each of theCell surface biotinylation was performed as described
five study groups as outlined in Table 1. Sodium-depen-previously [17]. Six-well plates with confluent OK cell
dent Pi transport was measured by 32Pi flux. Pi transportmonolayers were placed on ice and washed three times
in the absence of extracellular Na was less then 5% of thewith ice-cold phosphate-buffered saline (PBS) contain-
total uptake and was linear for the first 15 minutes. Fig-ing 1 mmol/L MgCl2 and 0.1 mmol/L CaCl2 (PBS C/M)
ure 1B shows that when compared with sera from controlto keep the epithelial layer tight. Cells were then incu-
subjects, sera from early post-transplant, dialysis andbated for 60 minutes at 4
C with N-hydroxysuccinimide
CRF (predialysis) patients inhibited Na-dependent Pibound via a disulfide bond to biotin (NHS-SS-biotin;
uptake by 26.2  2.9%, 36.3  10.2%, and 25.8  2.1%,Pierce, Rockford, IL, USA) at a final concentration of
respectively (P  0.05 vs. control). Sera from late post-1.5 mg/mL and freshly diluted into PBS C/M, from a
transplant patients did not affect Pi transport (90.8 200 mg/mL dimethyl sulfoxide (DMSO) stock stored at
3.6% vs. control; Fig. 1). This inhibitory effect of serum20
C. After that, cells were incubated for 20 minutes on
on Na/Pi cotransport is independent of Pi concentrationice in the presence of PBS C/M containing 100 mmol/L
in the media, since as shown in Figure 1A, even whenglycine to quench unbound labeling reagent, and were
the medium Pi was changed from 1 to 0.1 mmol/L duringthen washed once with PBS C/M to remove completely
the incubation period, sera from early post-transplant,any remaining quenching buffer. Subsequently, cells
dialysis and CRF (predialysis) patients inhibited Na/Piwere scraped in lysis buffer-RIPA (150 mmol/L NaCl, 5
uptake compared to control sera by 18.6  2.5%, 22.6 mmol/L EDTA, 50 mmol/L Tris, 1% Triton X100, 0.5%
3.3%, and 24.8  4%, respectively (P  0.0003 vs. con-sodium deoxycholate, 1% SDS, and a protease inhibitor
trol). Furthermore, although all hypophosphatemic pa-mix; Boehringer Mannheim). The samples were passed
tients during the early post-transplant period were treated10 times through a 1 mL syringe connected to a 25-G
by oral Pi preparations for at least three months, thisneedle, kept on a shaker for 30 minutes at 4
C, and
treatment had no influence on the effect of sera obtainedfinally centrifuged for 10 minutes at 10,000 g. A portion
from these patients. Thus, serum from early post-trans-of the resulting supernatant was retained as the total
plant patients inhibited 32P flux in OK cells regardlessfraction. The remainder was then agitated on a rotating
rocker overnight at 4
C with prewashed (three times with of whether serum Pi in the patients was corrected by
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Fig. 1. Changes in Na/Pi cotransport activity in response to 10% human sera. Opossum kidney cells were incubated overnight (20 hours) in
DMEM containing 0.1 (A) or 1 (B) mmol/L Pi and 10% serum from normal controls [N  5 (A), N  10 (B)], early post-transplant patients [N 
5 (A), N  14 (B)], late post-transplant patients [N  5 (A), N  9 (B)], patients treated with chronic hemodialysis [N  5 (A), N  10 (B)] or
patients with advanced chronic renal failure [CRF; N  5 (A) and (B)]. Na/Pi cotransport was measured as described in the Methods section. Bars
depict the mean  SEM. #P  0.05 vs. control; *P  0.03 vs. early post-transplant; 100%  4.73  0.46 (A) and 3.04  0.23 (B) nmol Pi/mg
protein/5 min.
cotransporter protein in OK cells (Na/Pi-4) was then
analyzed (Fig. 3). As shown in a representative immu-
noblot (Fig. 3B), OK cells incubated overnight with 10%
sera obtained from early post-transplant, dialysis, and
CRF (predialysis) patients expressed a marked increase
in the expression of Na/Pi-4 protein compared with OK
cells incubated overnight with 10% serum obtained from
a normal control subject. Densitometric analysis of the
data (Fig. 3A) demonstrates that 10% sera obtained
from early post-transplant, dialysis, and CRF (predialy-
sis) patients increase the abundance of Na/Pi-4 protein
by 238  25.9%, 189.4  22.7%, and 181  29.2%, re-
spectively, when compared with sera from normal con-
trol subjects (P  0.05 vs. control). Sera from late post-
transplant patients did not change the amount of Na/Pi-4
protein significantly compared to control sera. As shown
Fig. 2. Effect of 10% human sera on sodium-dependent phosphate in Figure 4, the effect of early post-transplant serum on
cotransport (Na/Pi; ) and glucose transport (). OK cells were incu- NaPi-4 was specific to this protein only since the serum did
bated overnight (20 hours) in DMEM containing 10% serum from
not change the abundance of two other proteins, namelynormal controls, early, or late post-transplant patients. Transport of Na
dependent Pi or glucose was assayed as described in the Methods actin and Glut-1. This figure also presents two individual
section. Bars depict the mean  SEM. *P  0.03 vs. control and late post-transplant patients from whom serum was taken
post-transplant.
within one month after transplantation (early) and then
again at three months following transplantation (late).
As can be shown, the effect of post-transplant serum
on augmentation of NaPi-4 protein already disappearedPi supplementation. The effect of serum on Na/Pi co-
after three months. We then investigated whether alter-transport was specific because it did not affect glucose
transport (Fig. 2). The expression of the type II Na/Pi ations in the Na/Pi-cotransport rate and in the amount
Green et al: Non-PTH mechanism hypophosphatemia1188
Fig. 3. Changes in the expression level of
type II Na/Pi cotransporter protein (Na/Pi-4)
in response to 10% human sera. OK cells were
incubated overnight in DMEM containing
10% serum from: normal controls (N  10),
early post-transplant patients (N 13), “late”
post-transplant patients (N  8), patients
treated by chronic hemodialysis (N  8), or
patients with advanced CRF (N  10). Then
cellular membranes were isolated, electropho-
resed on sodium dodecyl sulfate-polyacryl-
amide gel, and immunoblotted as described
in the Methods section. Na/Pi-4 signals were
quantitated by densitometry under conditions
where linearity was observed. (B) A represen-
tative Western blot and (A) the densitometric
analysis. The data shown depict the relative
abundance of Na/Pi-4 immunoreactive pro-
tein and are related to those observed in OK
cells incubated overnight with DMEM con-
taining 10% serum from normal controls. Bars
depict the mean SEM. #P 0.01 vs. control
and *P  0.001 vs. early post-transplant.
of Na/Pi-4 protein were paralleled by alterations in the
amount of Na/Pi-4 mRNA. Total RNA was isolated from
OK cells and analyzed by Northern blotting. A represen-
tative blot, demonstrated in Figure 5B, shows that the
augmentation in Na/Pi-4 protein is paralleled by in-
creased Na/Pi-4 mRNA. Thus, OK cells incubated over-
night with 10% sera obtained from early post-transplant,
dialysis, and CRF (predialysis) patients express a marked
increase in the amount of Na/Pi-4 mRNA compared with
OK cells incubated overnight with 10% serum obtained
from a normal control subject. Densitometric analysis of
the data shows increased mRNA expression by 300.1 
55.2%, 168  16.1%, and 171  22% by 10% sera ob-
tained from early post-transplant, dialysis, and CRF pa-
tients, respectively, when compared with sera obtainedFig. 4. Effect of 10% human sera on type II Na/Pi cotransporter (NaPi-4),
Glut-1, and actin immunoreactive proteins. OK cells were incubated from normal control subjects (P 0.05 vs. control). Sera
overnight in DMEM containing 10% serum from normal controls, early obtained from late post-transplant patients did not affect(2 to 4 weeks), or late (3 months) post-transplant patients. Then, cellular
the abundance of Na/Pi-4 mRNA.membranes were isolated, electrophoresed on sodium dodecyl sulfate-
polyacrylamide gel, and immunoblotted as described in the Methods To investigate whether excess PTH in the serum of
section. Representative gels from two membrane preparations per group transplant patients is responsible for the altered activityare shown. Each pair of early vs. late post-transplant serum represents
the same patient (that is, 2 pairs  2 patients). of the Na/Pi cotransporter as well as the change in the
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augmented expression of Na/Pi protein by early post-
transplant sera was inhibited when sera were coincu-
bated with PTH, indicating that the examined sera and
PTH act independently of one another. Furthermore,
the PTH antagonist [Nle8, Nle18, Tyr34] bovine PTH (3-34)
amide (105 mol/L) added to the incubation medium
four hours before starting the 32Pi flux assay did not af-
fect the inhibition of Pi transport when OK cells were
preincubated with 10% serum obtained from early post-
transplant, dialysis, and CRF patients (data not shown).
These results suggest that elevated PTH in the serum of
the different groups of patients cannot account for the
alterations in Pi transport and Na/Pi-4 protein expression
as observed in our study.
The specificity of our results was tested further by
performing time-course and serum-dose response exper-
iments. Figure 7A shows the time course of serum-de-
pendent inhibition of Na/Pi cotransport. When OK cells
were incubated for one hour with 10% sera from early
post-transplant patients (right) or patients on dialysis
(left), Na/Pi-4 cotransport activity was decreased signifi-
cantly when compared to control sera. Maximal inhibi-
tion was seen after four hours of incubation. Western
blots of Na/Pi-4 show a simultaneous increase in the
abundance of Na/Pi protein (Fig. 7B). A different time
course, however, was found for Na/Pi-4 mRNA abun-
dance (Fig. 7C). After four hours of incubation with 10%
serum from early post-transplant, CRF (predialysis), and
dialysis patients, Na/Pi-4 mRNA abundance was compa-
rable to the mRNA level observed with normal control
sera, whereas a strong increment was seen only at the
eight-hour time point. Figure 8A shows the concentra-
tion-dependent inhibition in Na/Pi cotransport after in-
Fig. 5. Changes in the expression level of type II Na/Pi cotransporter cubation for four hours with increasing concentrations
mRNA in response to 10% human sera. Total RNA was isolated from of serum obtained from early post-transplant (right) or
OK cells incubated overnight in DMEM containing 10% serum from
CRF (predialysis; left) patients. Significant differencesnormal controls (N  10), early post-transplant patients (N  15), late
post-transplant patients (N 8), patients treated by chronic hemodialysis between normal and CRF (left) or early post-transplant
(N  5), or patients with advanced CRF (N 5). After electrophoresis (right) sera were noted at concentrations of at least 8%
on agarose-formaldehyde gels, RNA was analyzed by Northern blotting
sera. A similar pattern of dose dependency was seenas described in the Methods section. The abundance of Na/Pi-4 mRNA
relative to cyclophylin was quantitated by densitometry under conditions when the increment of Na/Pi protein abundance was
where linearity was observed. (B) A representative Northern blot and assessed by Western blot analysis (Fig. 8B).
(A) the densitometric analysis. The data depict the relative abundance
To study the mechanism for the early increase in Na/of Na/Pi-4 mRNA relative to cyclophylin mRNA, and are related to
those observed in OK cells incubated overnight with DMEM containing Pi-4 protein abundance by sera from early post-trans-
10% serum from normal controls. Bars depict the mean  SEM. #P  plant patients and patients with CRF, it was necessary
0.05 vs. control; *P  0.01 vs. early post-transplant.
to differentiate between cell surface and intracellular
transporter. To that end, OK cells incubated for 4 or
20 hours with 10% sera from an early post-transplant
patient or with 10% control sera were labeled in theirexpression of the Na/Pi-4 protein, OK cells were pre-
incubated overnight with DMEM containing 10% sera surface membrane proteins NH2 groups, with a nonper-
meable biotin reagent, followed by strepavidin precipita-from the different groups and then four hours with or
without bovine PTH (1–34) (107 mol/L). Figure 6A shows tion and detection by Western blotting. This technique
allows for the detection of Na/Pi-4 cotransporters resid-that PTH (107 mol/L) inhibited Na/Pi cotransport rate
in all groups tested. In addition, Western blot analysis ing in the apical surface [17]. The Western blot analysis
represented in Figure 9 demonstrates that the increased(Fig. 6B) shows that PTH (107 mol/L) markedly reduced
the amount of NaPi-4 protein in all groups tested. Thus, amount of Na/Pi-4 protein seen in OK cells after 4 or
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Fig. 6. PTH inhibition of Na/Pi-4 cotransport
activity (A) as well as immunoreactive protein
(B) in OK cells incubated with 10% of the
different sera. OK cells were preincubated
overnight with DMEM containing 10% sera
from different subject groups as indicated, fol-
lowed by four hours of incubation with ()
or without () PTH (107 mol/L). The effect
of PTH was investigated by measuring Na/Pi
cotransport rate (A), as well as by immunode-
tection of the Na/Pi cotransporter by Western
blot (B). The data presented are from a typical
experiment. Similar results were obtained from
five separate experiments.
20 hours of incubation with 10% sera from an early post- contained in the urine is reabsorbed along the proximal
transplant patient (top row) is mainly attributable to en- tubule. Thus, increased FEPO4 in early post-transplant
hanced membrane-bound transporter (that is, biotinylated patients signifies impaired renal Pi reabsorption [7]. On
transporter; bottom row). In contrast, the intracellular pool the basis of the knowledge accumulated over the last few
of the transporter (middle row) is unaltered by post-trans- years, renal handling of Pi has been shown to be gov-
plant sera when compared with control sera. It appears, erned by specific Na/Pi cotransport proteins; proximal
therefore, that sera from early post-transplant, dialysis, tubular Pi reabsorption is mainly carried out by the type
and CRF patients lead to decreased endocytosis of the IIa Na/Pi cotransporter [7, 18]. Therefore, it is conceiv-
transporter from the cell surface into the cytosol. able that impaired renal Pi handing in transplant patients
is due to altered activity of type IIa Na/Pi cotransporter.
Even though the Na/Pi activity can be modulated by urineDISCUSSION
flow [19] and systemic acid-base changes [20, 21], thesePatients who have undergone kidney transplantation
variables could not account for the impaired Pi transportmanifest overt hypophosphatemia and exaggerated phos-
and phosphaturia in our patients, since the early post-phaturia during the early period following the transplan-
transplant patients were neither polyuric nor having ma-tation (that is, two weeks to one month after surgery).
jor deviations in serum pH (Table 2). Furthermore, givenThese abnormalities are manifested in the presence of
the inhibitory effect of PTH on Na/Pi IIa activity [7], post-stable and normal GFR. In contrast, patients in the late
transplant persistent HPT has been implicated in thepost-transplant period (9 to 12 months) have near-com-
pathogenesis of post-transplant hypophosphatemia [10].plete normalization of their serum Pi. Under normal
physiological conditions, approximately 80% of the Pi This mechanism, however, could not explain the hypo-
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Fig. 7. Time-dependent changes in Na/Pi-4 cotransport activity (A), immunoreactive protein (B), and mRNA abundance (C) in response to 10%
human sera. OK cells were incubated with DMEM containing 10% different sera for various time periods (as indicated). (A) Na/Pi-4 cotransport
activity of OK cells that were incubated for 0.5, 1, 2, or 4 hours with DMEM containing 10% serum obtained from dialysis (left) or early post-
transplant (right) patients. The data presented, expressed as nmol Pi/mg protein/5 min, are from a typical experiment. Similar results were obtained
from five separate experiments. (B) Immunoblots representing Na/Pi-4 protein expression of OK cells that were incubated for 0.5, 1, 2, or 4 hours
with DMEM containing 10% serum obtained from dialysis (left) or early post-transplant (right) patients. (C) Na/Pi-4 mRNA signals (relative to
cyclophylin mRNA) from Northern blots of OK cells incubated with 10% serum from the different experimental groups, as indicated in the picture
for four (left) or eight hours (right).
phosphatemia in our patient groups since most of the ing one hour of incubation and was maximal after four
hours. Sera from late post-transplant patients yieldedhypophosphatemic patients in the early post-transplant
period (15 out of 22) had normal levels of serum PTH. results comparable to control sera. The inhibition of Pi
transport by early post-transplant sera was specific sinceThe major thrust of our study is the notion that a hu-
morally mediated, non-PTH mechanism is responsible glucose transport was not affected. We could also demon-
strate a very clear concentration dependency of the in-for the inhibition of Na/Pi activity in transplant patients,
thereby leading to the in vivo abnormality of phosphatu- hibitory effect of serum on Na/Pi activity. Furthermore,
the effect of serum was independent of the ambient Piria and hypophosphatemia. To that end, we applied sera
from early and late post-transplant patients to the well- medium concentration since serum from early post-trans-
plant patients (as well as from the other groups) had thecharacterized and extensively studied proximal tubular
OK cells [13–15]. We found that early post-transplant same effect regardless of the overall Pi concentration in
the media bathing the cells during the incubation period.sera had a marked inhibitory effect on Na/Pi activity (as-
sayed as 32Pi flux). This effect was already evident follow- Likewise, the effect of early post-transplant sera was not
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Fig. 8. Concentration-dependent changes in Na/Pi-4 cotransport activity (A) and immunoreactive protein (B) in response to 10% human sera.
OK cells were incubated with DMEM containing 10% different sera (as indicated in the pictures) for four hours. (A) Na/Pi-4 cotransport activity
of OK cells that were incubated for four hours with DMEM containing 0, 2, 5, 8, or 10% serum from a CRF patient  10, 8, 5, 2, or 0% serum
from a normal control, respectively (left), or with DMEM containing 0, 2, 5, 8, or 10% serum from an early post-transplant patient  10, 8, 5, 2,
or 0% serum from a normal control, respectively (right). The data presented, expressed as nmol Pi/mg protein/5 min, are from a typical experiment.
Similar results were obtained from five separate experiments. (B) Immunoblots representing Na/Pi-4 protein expression of OK cells that were
incubated for four hours with DMEM containing different concentrations of CRF serum (mixed with normal control serum, as described previously
in this article; left) or different concentrations of early post-transplant serum mixed with normal control serum, as described in the text (right).
the inhibition of Na/Pi activity by early post-transplant sera
was paralleled by augmented expression of Na/Pi protein
abundance in OK cells (Na/Pi-4). Moreover, Na/Pi mRNA
was also increased, albeit at a later time point (following
8 hours of incubation as compared with 1 to 4 hours of
incubation for protein abundance). These findings, which
are discussed later, were not observed when OK cells
were incubated with sera from late post-transplant pa-
tients at which time serum Pi levels in the serum of the
patients were normal (that is, “normalization” of the
phenomena). Although most of our studies related to
the effect of late post-transplant sera have used sera
Fig. 9. Changes in the expression level of total, intracellular and cell from patients 9 to 12 months following transplantation,
surface Na/Pi-4 cotransporter protein in response to 10% human sera.
the effect of post-transplant sera on Na/Pi protein al-OK cells were incubated for 4 (left) or 20 hours (right) in DMEM
containing 10% serum obtained from a normal control subject or from ready disappeared at three months after transplantation,
an early post-transplant patient, as indicated in the picture. Then, cell- when compared with the effect of sera obtained within
surface biotinylation was performed as described in the Methods sec-
the first month following transplantation (Fig. 4).tion. Biotinylated proteins were recovered with strepavidin-agarose
beads. Total (top row), intracellular (middle row), and cell surface Glucocorticoids are important regulators of renal Pi
(bottom row) proteins were analyzed by SDS-PAGE, and transporter transport. Thus, the administration of glucocorticoids to
protein content was determined by Western blotting.
humans or experimental animals decreases tubular reab-
sorption of Pi due to inhibition of Na/Pi cotransport
[22]. Since the post-transplant patients in our study were
influenced by Pi treatment, which was prescribed to the taking steroids as part of their immunosuppressive regi-
hypophosphatemic patients, thereby suggesting that the men, one could argue that our results, showing inhibition
serum exerted an intrinsic suppressive effect on Na/Pi of Pi transport in OK cells by post-transplant sera, are
attributable to the use of steroids. We argue, however,activity. Interestingly and unexpectedly, our data show that
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that this is an unlikely possibility since careful analysis sera and post-transplant sera inhibited Pi transport over
and beyond the inhibition exerted by sera itself. Further-of the steroid effects on Na/Pi shows that the inhibition
of Pi transport is paralleled by a significant decrease in more, Western blot analysis shows that while early post-
transplant serum augments the abundance of the Na/Pithe abundance of Na/Pi mRNA and Na/Pi protein [22].
Our data, however, show increased abundance of the protein, the addition of PTH almost completely abro-
gates this increased expression. Even with late post-mRNA and the protein, and we believe, therefore, that
the inhibitory effect of sera on Pi transport cannot be transplant sera, which generate a modest increase in the
protein expression (albeit to a markedly smaller degreeascribed to glucocorticoid effect.
Our results demonstrate that the inhibition of Pi trans- compared with the early post-transplant sera), the addi-
tion of PTH dampens the intensity of the signal. Theseport in OK cells was observed not only when early post-
transplant sera was applied to the proximal tubular cells, results, when taken together, suggest that the sera used
in our study, on the one hand, and PTH, on the other,but also when using sera from patients with advanced
CRF or sera from end-stage renal disease (ESRD) pa- exert distinct effects on Na/Pi that act through indepen-
dent mechanisms. A non-PTH circulating factor thus maytients treated by chronic hemodialysis. Similar to the early
post-transplant patients, CRF patients also had increased contribute to Pi adaptation in CRF by inhibiting Na/Pi
type II activity and increasing FEPO4. This factor mayFEPO4, albeit at a higher serum Pi levels. Based on these
findings, we hereby set forth the hypothesis that a hu- then lead to hypophosphatemia when normal kidney
function is reinstated during the early period followingmorally mediated adaptation mechanism maintains Pi
homeostasis in renal failure by inhibiting Pi transport kidney transplantation.
A PTH-independent maintenance of Pi homeostasisand Na/Pi activity along the proximal tubule. Persistence
of this putative circulating factor for some time (weeks) achieved through increased FEPO4 and decreased NaPi-II
activity abundance in response to experimental renalfollowing successful renal transplantation could there-
fore lead to hypophosphatemia accompanied by in- failure has been also demonstrated by other investigators
[30–33]. Moreover, in agreement with our data, Rosen-creased phosphaturia. Current opinion maintains that as
nephron mass is progressively diminished in CRF, the baum et al demonstrated 20 years ago that hypophos-
phatemia following transplantation was unaffected evenadaptive response to dietary Pi involves increased Pi
excretion by the remaining nephrons [23]. According to when PTH levels were suppressed by intravenous cal-
cium infusion [2].this notion, the adaptive response is mediated by ele-
vated PTH levels in CRF [8, 9]. Thus, increased PTH The presence of a circulating phosphaturic factor in
our patients (early post-transplant, CRF, and dialysisproduction, probably triggered by hyperphosphatemia,
leads to a reduced proximal tubular Pi reabsorption due patients) adds to the spectrum of the various hypophos-
phatemic disorders in which a putative hormone refer-to reduced Na/Pi activity [24]. This response will, in turn,
maintain Pi serum levels at normal values until GFR enced as “phosphatonin” down-regulates the activity of
Na/Pi cotransporter in the proximal tubule, thereby caus-drops to less than 25% of normal [25]. With this back-
ground in mind, we now argue that the phosphaturic ing phosphaturia. Two disorders that have in common ab-
normal humorally mediated, increased renal clearanceeffect of PTH cannot account for the inhibition of Pi
transport in OK cells by the different sera used in our of Pi and hypophosphatemia are X-linked hypophos-
phatemic rickets (XLH) and tumor-induced osteomala-study. This argument is based on the following: (1) As
stated previously in this article, a large proportion of cia (TIO) [34–38].
X-linked hypophosphatemia occurs as an X-linkedpatients both from the early post-transplant group and
from the CRF group had normal levels of PTH, yet their dominant disorder with complete penetrance of a renal
tubular abnormality resulting in Pi wasting and conse-sera exerted the changes in Na/Pi activity. (2) A large
body of evidence accumulated over the recent years has quent hypophosphatemia. It is the prototypic renal Pi
wasting disorder, characterized in general by progres-clearly shown that PTH inhibits Na/Pi cotransport by
retrieval of the transporter from the apical membrane sively severe skeletal abnormalities and growth retarda-
tion. The hyp-mouse model harbors a homologous muta-followed by lysosomal degradation [26–29]. In contrast,
our data show increased rather than decreased expres- tion and is an excellent mimic of the human disease.
Current studies have provided compelling evidence thatsion of both the protein and mRNA of Na/Pi, when OK
cells are incubated with early post-transplant sera. In the defect in renal Pi transport in XLH is secondary to
the effects of a circulating hormone or metabolic factoraddition, the PTH antagonist, [Nle8, Nle18, Tyr34] bovine
PTH (3-34) amide did not affect the inhibitory effect of [35]. The identity of the putative factor, the spectrum of
its activity, and the mechanism by which it functions havethe sera on Pi transport. To our mind, the most convinc-
ing evidence that argues against the possibility of PTH not been definitively elucidated. Regardless, preliminary
reports suggest the production of a phosphaturic factoreffect mediating our results is presented in Figure 6. Ac-
cording to these data, the addition to PTH to control by hyp-mouse osteoblasts and marrow mesenchymal cells
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maintained in culture [35]. This factor (“phosphatonin”) adaptation in CRF and generates phosphaturia and hy-
pophosphatemia following kidney transplantation. Withexerts a persistent defect in renal Pi transport likely
caused by decreased expression of Na/Pi-type II protein this postulated scenario, it is clear that “phosphatonin”
represents a heterogeneous family of phosphaturic hor-and mRNA [39, 40]. The recent discovery of the PHEX
gene (Pi-regulating gene with homologies to endopepti- mones with different properties and modes of action.
This notion, also put forth by other investigators, is sup-dases on the X-chromosome) has provided new insights
to these disorders [34]. Thus, under normal conditions, ported by our data showing that decreased Pi transport
by phosphatonin was associated with increased expres-PHEX (also expressed in osteoblasts) degrades a sub-
stantial quantity of the active phosphatonin, rendering it sion of Na/Pi-type 2 mRNA and protein [11]. This effect
stands in sharp contrast to the effect of phosphatoninan inactive metabolite that is unable to affect Pi transport
along the proximal tubule. An inactivation mutation in XLH, where impaired Pi transport is paralleled by
decreased mRNA and protein of the transporter [39, 40].of the PHEX gene in XLH causes a failure to inactivate
phosphatonin. This enables active phosphatonin to in- Our studies indicate that the Na/Pi inhibitory effect
of sera from the different patient groups (early post-hibit type II Na/Pi in the proximal tubule, thereby leading
to increased renal clearance of inorganic Pi and hypo- transplant patients, CRF and dialysis patients) was paral-
leled by an increased abundance of Na/Pi protein andphosphatemia.
In contrast to XLH, TIO is a sporadic condition char- mRNA in OK cells. Time-course analysis revealed that
the increase in protein expression (by Western blot anal-acterized by the remission of bone disease after resection
of a coexisting tumor. The tumors have been of mesen- ysis) was already evident after one hour of incubation,
a time point roughly corresponding to the early inhibi-chymal origin in the large majority of patients. There is
strong evidence that a humoral factor produced by the tion of Pi transport (that is, Na/Pi activity). In contrast,
a significant increase in mRNA abundance was only seentumor is likewise responsible for TIO. This possibility
has been supported by (1) the inhibition of Pi uptake in after eight hours of incubation. This time-course pattern
suggests that the early inhibition of Pi transport in theOK cells by conditioned medium collected from cultured
tumor cells obtained from affected patients [36, 37] and proximal tubule is probably related to a post-transla-
tional event. Thus, the putative phosphatonin could inac-(2) the presence of phosphaturic activity in tumor ex-
tracts from three of four patients with TIO [38]. Indeed, tivate Na/Pi either by direct interaction with the trans-
porter or by interacting with an intermediary factor, which,partial purification of “phosphatonin” from a cell culture
of a sclerosing hemangioma causing TIO has reaffirmed in turn, inactivates Na/Pi. Our results with the biotinyla-
tion assay (Fig. 9) indicate that the early rise in Na/Pithe concept of a tumor-derived factor [41]. These studies
reveal that the putative phosphatonin may be a peptide protein abundance by early post-transplant sera is mainly
due to increased membrane-bound transporter. Thus, in-with molecular weight of 8 to 25 kD, which does not
alter glucose or alanine transport but inhibits sodium- activation of Na/Pi by “phosphatonin” (causing phospha-
turia and hypophosphatemia in post-transplant patients)dependent Pi transport. Rowe et al have reported that
screening of conditioned medium from the tumor cells probably leads to decreased shuttling of the transporter
(that is, decreased endocytosis), which could then ac-of an affected patient, using an antiserum raised preoper-
atively, and subsequent Western analysis revealed the count for the increase in total Na/Pi protein content
(possible decreased lysosomal degradation). Alterna-presence of two proteins of 56 and 58 kD [42]. More re-
cently, they have successfully extracted mRNA from a tively, mislocalization of Na/Pi protein (that is, residing
predominantly in the apical membrane due to defectivetumor in an affected patient and cloned a novel gene that
codes for a protein of over 430 residues with N-glycosyla- endocytosis) could affect its function leading to hyper-
phosphaturia. Such a mechanism has been recently sug-tion motifs and glycosaminoglycan attachment sites.
Similar to XLH, the mechanism of action by which gested to play a role in the pathogenesis of Dent’s disease
(a ClC-5 Cl-channel mutation causing X-linked kidneyphosphatonin functions in TIO remains unknown. How-
ever, in contrast to XLH where an unopposed effect of stone disease) [43]. Regardless of the sequence of events,
we speculate that the inhibition of Pi entry into the cellphosphatonin results from mutation of PHEX, TIO
likely evolves secondary to tumor overproduction of the could lead, on a chronic basis, to intracellular Pi deple-
tion. The Pi depletion, after several hours, then wouldputative phosphatonin, which exerts physiologic func-
tion, namely, inhibition of proximal Pi reabsorption. In lead to an up-regulation of Na/Pi mRNA that would
further augment protein abundance by a post-transcrip-spite of concomitant overproduction of PHEX, this in it-
self is not enough to counteract phosphatonin’s effect, tional translational mechanism [44]. The increased pro-
tein abundance is not sufficient, however, to overcomedue to the enhanced substrate load.
Given this role of phosphatonin in the pathophysiol- the inhibitory effect of phosphatonin on Na/Pi activity.
While some segments of this scheme (summarized inogy of hypophosphatemic disorders, our data suggest
that a “phosphatonin-like” substance contributes to Pi Fig. 10) are speculative, it is nonetheless clear that hypo-
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Fig. 10. A schematic model of our working
hypothesis related to the pathogenesis of post-
transplant hypophosphatemia brought about
by circulating “phosphatonin.” Details are dis-
cussed in the text.
phosphatemic patients in the early post-transplant period after transplantation (vs. sera of 1 month allowing trans-
plantation) suggests that the putative “phosphatonin” inmanifest intracellular Pi depletion. Thus, in a group of
hypophosphatemic patients after renal transplantation (1 the serum of transplant patients acts for a relatively short
duration of time. Further studies are warranted in ordermonth) measurements of muscular Pi concentration by
to determine the nature of “phosphatonin” in CRF and31Pi nuclear magnetic resonance (NMR) spectroscopy
transplant patients (a cytokine? lipid? hormone?). Also,have shown a marked skeletal muscle Pi depletion that
the site of elaboration of this type of phosphatonin asnormalizes within 12 weeks after transplantation [45, 46].
well as the mechanisms that trigger its production inBased on these observations, it is conceivable that the
CRF needs to be explored further.presence of phosphatonin in transplant patients leads to
Pi depletion in the proximal tubular cells, which could
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bated with sera from patients with progressive CRF Abbreviations used in this article are: ADPKD, autosomal-domi-
and ESRD patients treated by chronic hemodialysis. We, nant polycystic kidney disease; BBM, brush-border membrane; CRF,
chronic renal failure; CsA, cyclosporine; DMEM, Dulbecco’s modifiedtherefore, believe that a non-PTH phosphaturic factor
Eagle’s medium; DMSO, dimethyl sulfoxide; ECL, enhanced chemilu-in the serum of CRF contributes to Pi adaptation by in- minescence; EDTA, ethylenediaminetetraacetic acid; ESRD, end-
hibiting Pi reabsorption and increasing FEPO4. Persistence stage renal disease; FEPO4, fractional excretion of Pi; GFR, glomerular
filtration rate; HPT, hyperparathyroidism; MMF, mycophenolate mo-of this factor into the early post-transplant period would
fetil; NMR, nuclear magnetic resonance; OK, opossum kidney; PBScause phosphaturia and hypophosphatemia in these pa- C/M, phosphate-buffered saline with MgCl2 and CaCl2; PHEX, phos-
tients. The up-regulation of Na/Pi protein abundance by phate-regulating gene with homologies to endopeptidases on the
X-chromosome; Pi, phosphate; PTH, parathyroid hormone; TBS, Tris-early post-transplant sera derives from both post-transla-
buffered saline; TIO, tumor-induced osteomalacia; TMA, tetramethyl-tional and post-transcriptional mechanisms. This study ammonium chloride; TMPO4/GFR, renal phosphate threshold; XLH,
lends credence to the concept of the “phosphatonin” X-linked hypophosphatemia.
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